However, from the perspective of drug delivery, cationic AMPs, and PD‐L1 antagonist peptides are easily degraded and cleared by the reticulo‐endothelial system (RES) after systemic administration.[12b] Furthermore, most AMPs hardly cross cell membrane and escape from endosomes, which severely limits their bioactivity in tumor inhibition and cGAS‐STING pathway activation.[13] Thus, it is necessary to design a feasible strategy to deliver PD‐L1 antagonist peptides and AMPs into specific action sites (tumor extracellular and intracellular) while maintaining low normal tissue toxicity. The gene discussed is ADSL; the disease is neoplasm.